Market Overview

Benzinga's Top Initiations

Share:
Benzinga's Top Initiations
Related ALXN
Alexion Pharma Brexit Selloff Creates An Entry Point: Trading At 'Dark-Sky' Valuation
Benzinga's Top Upgrades
Biotech Strategy Following Brexit: Run, Don't Walk (Seeking Alpha)
Related DHR
Barclays Expects A 'Tangible Catalyst' For Danaher Corp This Summer
Benzinga's Top Upgrades
4 Reasons I Bought Danaher (Seeking Alpha)

Analysts at Citigroup initiated coverage on shares of Alexion Pharmaceuticals (NASDAQ: ALXN) with a “neutral” rating. Alexion's shares closed at $93.59 yesterday. Alexion's trailing-twelve-month operating margin is 35.20%.

BMO Capital initiated coverage on shares of Danaher (NYSE: DHR) with an “outperform” rating. Danaher's shares closed at $53.07 yesterday. Danaher's trailing-twelve-month revenue is $18.00 billion.

SunTrust initiated coverage on shares of Citigroup (NYSE: C) with a “buy” rating. Citigroup's stock closed at $37.02 yesterday. Citigroup had $798.78 billion in total cash for the recent quarter.

Analysts at Wedbush initiated coverage on shares of Oracle (NASDAQ: ORCL) with a “neutral” rating. Oracle's shares closed at $32.03 yesterday. Oracle's PEG ratio is 1.00.

Latest Ratings for ALXN

DateFirmActionFromTo
Jun 2016CitigroupUpgradesNeutralBuy
Jun 2016Morgan StanleyMaintainsOverweight
Apr 2016BMO CapitalUpgradesMarket PerformOutperform

View More Analyst Ratings for ALXN
View the Latest Analyst Ratings

Posted-In: Top InitiationsInitiation Analyst Ratings

 

Related Articles (ALXN + C)

View Comments and Join the Discussion!